SCHEMBL29925784

SCHEMBL29925784

O=C1COc2cncc(c2)-c2n[nH]c3ccc(cc23)OCCN1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.44
CLK2 P49760 5/20 0.44
GSK3B P49841 4/20 0.44
CLK3 P49761 4/20 0.44
LRRK2 Q5S007 5/20 0.39
MAP2K4 P45985 2/20 0.35
PIM1 P11309 3/20 0.33
AXL P30530 1/20 0.33
MAPK1 P28482 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
MAPKAPK3 Q16644 1/20 0.33
MAPK6 Q16659 1/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
DCLK1 O15075 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
CSF1R P07333 1/20 0.33
FER P16591 1/20 0.33
CDK2 P24941 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27031760 0.94 DYRK1A (0.43) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL29925212 0.94 DYRK1A (0.43) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL29925739 0.86 DYRK1A (0.45) DYRK1ACLK2GSK3BCLK3MAP2K4
SCHEMBL29925496 0.83 GSK3B (0.39) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL29925849 0.83 GSK3B (0.39) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL27031742 0.83 GSK3B (0.39) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL27031843 0.83 GSK3B (0.39) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL29925262 0.82 DYRK1A (0.45) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL27031807 0.82 DYRK1A (0.45) DYRK1ACLK2GSK3BCLK3LRRK2
SCHEMBL29925502 0.82 GSK3B (0.44) DYRK1ACLK2GSK3BCLK3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 US claimed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 EP claimed
WO-2022194976-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-09-22 WO claimed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 US disclosed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 EP disclosed
WO-2022194976-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 DYRK1A 993/4885CLK2 16/4885GSK3B 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.